研究人员对接受新辅助化疗的II期乳腺癌患者进行了研究。
To investigate, the researchers studied stage II and II breast cancer patients who were receiving neoadjuvant chemotherapy.
目的探讨新辅助化疗在晚期乳腺癌治疗中的效果。
Objective To study the clinical effect of neoadjuvant chemotherapy on advanced breast cancer.
前言： 目的：探讨新辅助化疗在局部晚期乳腺癌治疗中的应用。
Objective: To evaluate the effect of neoadjuvant chemotherapy in the treatment of locally advanced breast cancer.
方法：回顾性分析32例局部晚期乳腺癌患者进行新辅助化疗的临床资料。
Methods: 32 patients with locally advanced breast cancer treated by neoadjuvant chemotherapy were reviewed retrospectively.
选择性COX - 2抑制剂可联合化疗、内分泌治疗及生物治疗等，作为肿瘤治疗的辅助药物应用于临床，为乳腺癌的治疗提供一种新的途径。
Selective COX-2 inhibitors can combine with chemotherapy, endocrine therapy and biotherapy. It is gradually used for adjunctive therapy and provides a new pathway for the therapy of breast cancer.
目的：探讨新辅助化疗在老年乳腺癌患者治疗中的意义。
Objective: To evaluate the significance of neoadjuvant chemotherapy in elder breast cancer patients.
现就新辅助化疗在乳腺癌治疗中的现状及展望作一综述。
This review presents the present state and future prospect of neoadjuvant chemotherapy for advanced breast cancer.
目的：研究表柔比星加紫杉醇新辅助化疗方案治疗乳腺癌的近期疗效及毒副反应。
Purpose: To study the short-term efficacy and toxicity of the neoajuvant chemotherapy with epirubicin (EPI) plus paclitaxel( TAX) in treatment of patients with breast cancer.
观察和探讨CEF方案在乳腺癌新辅助化疗应用中的临床疗效。
Objective To observe and discuss the clinical effect of CEF new accessorial chemotherapy project in treating breast cancer.
目的：观察中医扶正培本治疗对乳腺癌新辅助化疗患者细胞免疫功能的影响。
Objective:To observe the effects of neoadjuvant chemotherapy and neoadjuvant chemotherapy plus Shenqi Fuzheng Injection on cell immunofunction in patients with breast cancer.
目的探讨CAF方案在乳腺癌短周期密集新辅助化疗中的安全性、近期疗效以及对手术方式的影响。
Objective to evaluate the security and response rate of short cycle neoadjuvant chemotherapy with dose-dense CAF regime in breast cancer, and to explore which effect on the pattern of surgery.
目的评价CEF方案新辅助化疗治疗局部晚期乳腺癌的临床疗效和毒性反应。
Objective to evaluate the clinical efficacy and toxicity of CEF as the neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer (LABC).
目的：探讨乳腺癌新辅助化疗对耐药基因mdr1和MRP表达的影响。
AIM: To investigate the expression of drug resistance genes, MDR1 and MRP, in patients with primary breast cancer after neoadjuvant chemotherapy.
目的了解心理行为干预对乳腺癌新辅助化疗患者情绪及免疫功能的影响。
Objective To learn about the influence of psychological and behavioral intervention on the emotion and immune function of patients undergoing breast cancer neo-adjuvant chemotherapy.
目的通过研究新辅助化疗对乳腺癌根治术后病理分期及治疗方案的影响，进一步评价新辅助化疗的临床价值。
Objective To evaluate the clinical value of neoadjuvant chemotherapy for breast cancer on pathological stage and designing of therapy plan.
目的探讨术前新辅助化疗对乳腺癌的疗效及提高患者术后生存率的作用。
To explore the effect of new auxiliary chemotherapy before operation on treating local mammary cancer of late stage and prolonging the life of the cancer patients.
目的研究新辅助化疗在中晚期乳腺癌保乳治疗中的应用价值。
Objective To study the value of pre-operative chemotherapy combined with breast conservation surgery for the treatment of middle-advanced breast cancer.
术前辅以新辅助化疗，术后辅以正规内分泌治疗是提高局部晚期乳腺癌生存率的必要手段。
The neoadjuvant chemotherapy and regular endocrine therapy are the necessary measures to improve the survival rates of locally advanced breast cancer.
乳腺癌术前化疗即新辅助化疗，使局部进展期乳腺癌的治疗取得了重大进展。
Nowadays, neoadjuvant chemotherapy, which is raised by clinic, made a big breakthrough in breast cancer partial treatment progression.
方法：应用电镜观察20例新辅助化疗组和20例对照组乳腺癌细胞超微结构的变化。
Method: the ultrastructure of 20 cases of human breast carcinoma after neoadjuvant chemotherapy and the ultrastructure of 20 cases of control group were observed by transmission electron microscope.
目的：探讨乳腺癌病人新辅助化疗后前哨淋巴结活检的可行性。
Objective: To study the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy for breast cancer.
摘要：目的研究高强度聚焦超声(HIFU)联合新辅助化疗治疗乳腺癌的治疗疗效。
Abstract: Objective To investigate the therapeutic effects of breast cancer after high intensity focused ultrasound (HIFU) combined with neoadjuvant chemotherapy.
目的：探讨乳腺癌特异基因(BCSG1)在乳腺癌新辅助化疗疗效评估中的价值。
Objective: To study the value of BCSG1 on evaluating the curative effect of neoadjuvant chemotherapy (nc) for breast cancer.
方法采用免疫组织化学法检测55例乳腺癌新辅助化疗前后标本中MCM7的表达。
Methods An immunohistochemistry was used to measure the expressions of MCM7 before and after neoadjuvant chemotherapy for 55 cases of breast cancer.
结论ET方案新辅助化疗有较好的疗效，可能通过抑制MCM 7蛋白的表达来阻止乳腺癌细胞的增殖。
Conclusion Neoadjuvant chemotherapy with ET regimen is effective, and it may inhibit the proliferation of breast cancer cell by down-regulation of the expression of MCM7.
目的探讨乳腺癌新辅助化疗前后M CM 7蛋白的表达状况，分析其与化疗效果的关系。
Objective to study the expressions of MCM7 before and after neoadjuvant chemotherapy in patients with breast cancer, and to analyze its relationship with response to neoadjuvant chemotherapy.
目的探讨参麦注射液联合新辅助化疗te方案治疗乳腺癌的疗效和对乳腺癌患者生活质量的影响。
Objective to investigate the efficacy of Shenmai injection combined te chemotherapy regime in the treatment of breast cancer and the influence to the quality of life in breast cancer patient.
目的探讨参麦注射液联合新辅助化疗te方案治疗乳腺癌的疗效和对乳腺癌患者生活质量的影响。
Objective to investigate the efficacy of Shenmai injection combined te chemotherapy regime in the treatment of breast cancer and the influence to the quality of life in breast cancer patient.
应用推荐